ARCA biopharma, Inc. (ABIO) News
Filter ABIO News Items
ABIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ABIO News From Around the Web
Below are the latest news stories about ARCA BIOPHARMA INC that investors may wish to consider to help them evaluate ABIO as an investment opportunity.
ARCA biopharma Announces Third Quarter 2023 Financial ResultsCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Dir |
ARCA biopharma Announces Second Quarter 2023 Financial ResultsCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Di |
We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
ARCA biopharma Announces First Quarter 2023 Financial ResultsCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., April 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Dir |
ARCA biopharma Announces 2022 Financial Results and Provides Corporate UpdateCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Th |
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
James Flynn Joins ARCA biopharma Board of DirectorsWESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium |